Table 5.

A non-exhaustive representative summary of key clinical trials evaluating radiotherapy in combination with immune checkpoint inhibition.

NCT number	Combination	Study design	Findings
NCT02125461	Sequential Durvalumab after concurrent chemoradiotherapy (PACIFIC trial)	Phase 3, stage III unresectable NSCLC	Median PFS 16.8 months (Durvalumab) vs 5.6 months (placebo)
NCT02444741	50 Gy in 5 fractions SBRT + concurrent Pembrolizumab	Phase 1/2, metastatic NSCLC	Improved ORR, did not reach statistical significance
NCT02492568	24 Gy in 3 fractions + sequential Pembrolizumab	Phase 2, metastatic NSCLC	Improved ORR, did not reach statistical significance
NCT02904954	24 Gy in 3 fractions SBRT+ concurrent Durvalumab prior to surgical resection	Phase 2, stage I, II, IIa NSCLC, neo-adjuvant	Significantly higher major pathological response rate with combination treatment (53.3%) vs single agent Durvalumab (6/7%)
NCT02221739	30 Gy in 5 fractions (later 28.5 Gy in 3 fractions) RT + concurrent Ipilimumab	Phase 1/2, metastatic NSCLC.	Evidence of response in 33% of evaluable patients.
NCT01557114	9, 15, 18 or 24 Gy in 3 fractions RT + concurrent Ipilimumab	Phase 1, advanced melanoma	31% ORR, increased CD8+ T cells associated with improved PFS
NCT02684253	27 Gy in 3 fractions + concurrent Nivolumab	Phase 2, HNSCC	No improvement in response and no evidence of abscopal effect
NCT02730130	30 Gy in 5 fractions + concurrent Pembrolizumab	Phase 2, TNBC	ORR 17.6%, 3/17 CR
NCT03051672	20 Gy in 5 fractions + Pembrolizumab 2-7 days prior then every 21 days	Phase 2, metastatic hormone receptor positive, HER-2 negative breast cancer	No objective responses, median OS 2.9 months
NCT02311361	8 Gy single fraction or 25 Gy in 5 fractions + Durvalumab/Tremelimumab/dual ICPI	Phase 1/2, PDAC	ORR 5.1%, PFS between 0.9 and 9 months depending on treatment cohort